Shares of SeaSpine Holdings Corp (NASDAQ:SPNE) have been assigned an average rating of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $21.00.
Several research analysts recently issued reports on SPNE shares. ValuEngine lowered shares of SeaSpine from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. BidaskClub cut shares of SeaSpine from a “hold” rating to a “sell” rating in a research note on Tuesday, March 5th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $22.00 price objective on shares of SeaSpine in a research note on Thursday, May 2nd. BTIG Research reaffirmed a “buy” rating and set a $20.00 price objective on shares of SeaSpine in a research note on Sunday, March 31st. Finally, Zacks Investment Research cut shares of SeaSpine from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th.
In other SeaSpine news, major shareholder Richard E. Caruso sold 5,020 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $15.17, for a total transaction of $76,153.40. Following the sale, the insider now directly owns 20,477 shares of the company’s stock, valued at $310,636.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 12.47% of the stock is currently owned by corporate insiders.
NASDAQ:SPNE opened at $14.25 on Thursday. SeaSpine has a 12-month low of $11.16 and a 12-month high of $20.75. The stock has a market capitalization of $269.30 million, a P/E ratio of -6.54 and a beta of 0.06.
SeaSpine (NASDAQ:SPNE) last posted its quarterly earnings results on Wednesday, May 1st. The medical equipment provider reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.06). SeaSpine had a negative return on equity of 30.07% and a negative net margin of 24.18%. The business had revenue of $36.15 million during the quarter, compared to analyst estimates of $35.72 million. Analysts expect that SeaSpine will post -1.72 EPS for the current fiscal year.
SeaSpine Company Profile
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine.
Featured Article: Should I follow buy, hold and sell recommendations?
Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.